HSCT

HSCT | Briquilimab Granted Orphan Drug Designation By The European Commission

Previously, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to briquilimab in HCT, as well as rare pediatric disease designation for the treatment of severe combined immunodeficiency…